ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 281 filers reported holding ROYALTY PHARMA PLC in Q2 2022. The put-call ratio across all filers is 0.10 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $19,536,647 | +5.4% | 719,847 | +19.4% | 0.00% | +33.3% |
| Q2 2023 | $18,534,345 | -8.7% | 602,939 | +7.0% | 0.00% | -25.0% |
| Q1 2023 | $20,307,805 | -10.4% | 563,636 | -1.7% | 0.00% | -33.3% |
| Q4 2022 | $22,661,954 | -35.6% | 573,430 | -34.5% | 0.01% | -33.3% |
| Q3 2022 | $35,197,000 | +4.7% | 876,000 | +9.5% | 0.01% | +12.5% |
| Q2 2022 | $33,624,000 | +141.5% | 799,800 | +123.8% | 0.01% | +300.0% |
| Q1 2022 | $13,925,000 | -48.2% | 357,400 | -47.0% | 0.00% | +100.0% |
| Q4 2021 | $26,868,000 | +180.4% | 674,192 | +154.3% | 0.00% | -50.0% |
| Q3 2021 | $9,581,000 | -44.8% | 265,100 | -37.4% | 0.00% | -33.3% |
| Q2 2021 | $17,361,000 | -45.2% | 423,527 | -41.7% | 0.00% | -40.0% |
| Q1 2021 | $31,665,000 | +3.4% | 725,920 | +18.6% | 0.01% | +150.0% |
| Q4 2020 | $30,636,000 | +165.7% | 612,106 | +123.3% | 0.00% | -33.3% |
| Q3 2020 | $11,531,000 | +244.1% | 274,108 | +297.2% | 0.00% | – |
| Q2 2020 | $3,351,000 | – | 69,013 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $294,957,000 | 88.74% |
| Vantage Consulting Group Inc | 8,705,551 | $379,735,000 | 76.23% |
| Memorial Sloan Kettering Cancer Center | 2,680,644 | $116,930,000 | 72.07% |
| HARVARD MANAGEMENT CO INC | 10,714,284 | $467,357,000 | 26.11% |
| ROBERT WOOD JOHNSON FOUNDATION | 970,151 | $4,231,798,000 | 21.59% |
| Brown University | 381,759 | $16,652,000 | 11.44% |
| Overbrook Management Corp | 771,155 | $33,638,000 | 7.48% |
| SpiderRock Advisors, LLC | 778,800 | $34,236,000 | 4.79% |
| Renaissance Capital LLC | 452,948 | $19,758,000 | 2.93% |
| Lagoda Investment Management, L.P. | 104,835 | $4,573,000 | 2.28% |